A closer look at copanlisib.
Authors: Dreyling M PMID: 29741503 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Research in drug development for advanced prostate cancer.
Authors: Eisenberger M PMID: 29741504 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Checkpoint inhibition in lymphoma.
Authors: Shah GL, Moskowitz CH Abstract Checkpoint inhibition improves surveillance by the immune system and therefore outcomes in some lymphoma subtypes. In this review, we examine the available evidence regarding checkpoint inhibition in lymphoma by line of therapy. Although most published studies are in the setting of relapsed/refractory disease, several ongoing trials are looking at therapy in the upfront and second-line settings. Nivolumab and pembrolizumab have been approved for patients with relapsed or refractory Hodgkin lymphoma, whereas other programmed death 1 and programmed death ligand 1 monoclonal ant...
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches.
Authors: Brunner AM, Steensma DP Abstract It has been more than 10 years since any new disease-modifying therapies have received regulatory approval for indications related to myelodysplastic syndromes (MDS). Advances in our collective biological understanding of MDS in the last decade, however, have made it possible to hope that effective therapeutics can be designed to improve MDS-associated cytopenias and patients' quality of life, and perhaps even delay clonal progression and extend survival. Classes of MDS-associated mutations and disordered biological pathways targeted by developmental therapeutics include th...
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Cabozantinib approved for first-line treatment of advanced renal cell carcinoma.
Authors: PMID: 29741507 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How to manage patients with moderate-risk germline mutations.
Authors: Tung NM PMID: 29741508 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The development of endoxifen for breast cancer.
Authors: Goetz MP PMID: 29741509 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How we treat brain metastases in metastatic renal cell carcinoma.
Authors: Ramalingam S, George DJ, Harrison MR PMID: 29741510 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Current and emerging first-line systemic therapies in clear cell renal cell carcinoma.
Authors: Rini BI PMID: 29741511 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in CAR T-cell therapy for chronic lymphocytic leukemia.
Authors: Porter DL PMID: 29741512 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Myelofibrosis: clinicopathologic features, prognosis, and management.
Authors: O'Sullivan JM, Harrison CN Abstract Myelofibrosis is one of the BCR-ABL-negative clonal disorders that collectively are known as myeloproliferative neoplasms (MPNs). It is caused by the proliferation of clonal hematopoietic stem cells, which over time leads to characteristic clinical features. The disease presentation is heterogeneous, however, with 30% of patients initially asymptomatic. This variation in clinical phenotype warrants careful risk stratification to guide appropriate management, and prognostic risk scores are continually being refined. Considerable advancements have been made in the understa...
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Management of acute lymphoblastic leukemia in young adults.
Authors: Muffly LS, Reizine N, Stock W Abstract Substantial interest in acute lymphoblastic leukemia (ALL) in young adults (YAs) and investigations focused on this patient population have resulted in therapeutic advancements that are changing the management paradigm and improving outcomes. The pediatric ALL approach is feasible and effective when administered by medical oncologists. Advanced diagnostics and minimal residual disease measurements aid in prognostication and have resulted in shifting recommendations regarding allogeneic hematopoietic cell transplant in first remission. Blinatumomab, inotuzumab, and chi...
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Cost-effectiveness in the surgical care of renal cell carcinoma.
Authors: PMID: 29742072 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Are direct acting oral anticoagulants ready for prime-time use in cancer-related thrombosis?
Authors: Streiff MB PMID: 29742073 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Emerging options for combination therapy in multiple myeloma.
Authors: Rossi AC PMID: 29742074 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The timing of molecular imaging in prostate cancer.
Authors: Morris MJ PMID: 29742075 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Update on hairy cell leukemia.
Authors: Kreitman RJ, Arons E Abstract Hairy cell leukemia (HCL) is a chronic B-cell malignancy with multiple treatment options, including several that are investigational. Patients present with pancytopenia and splenomegaly, owing to the infiltration of leukemic cells expressing CD22, CD25, CD20, CD103, tartrate-resistant acid phosphatase (TRAP), annexin A1 (ANXA1), and the BRAF V600E mutation. A variant lacking CD25, ANXA1, TRAP, and the BRAF V600E mutation, called HCLv, is more aggressive and is classified as a separate disease. A molecularly defined variant expressing unmutated immunoglobulin heavy variable 4-3...
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.
Authors: Yilmaz M, Kantarjian H, Ravandi-Kashani F, Short NJ, Jabbour E Abstract Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) accounts for approximately one-fourth of cases of adult ALL. It typically presents with an aggressive clinical course, responds poorly to standard chemotherapy, and carries a high risk for relapse. The landscape of Ph+ ALL therapy has changed favorably since the development of tyrosine kinase inhibitors (TKIs). With the successful incorporation of TKIs into chemotherapy regimens, remissions occur more frequently and patients live longer. Imatinib was the first TK...
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation.
Authors: DiNardo C PMID: 29742078 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Current approaches to pregnancy and childbirth in women with von Willebrand disease.
Authors: Johnsen JM PMID: 29742079 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Bayesian approaches to evaluating doses of drugs.
Authors: Rosner GL PMID: 29742080 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Looking ahead to new therapies in small cell lung cancer.
Authors: Rudin CM PMID: 29742081 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Update on signal inhibitors in chronic lymphocytic leukemia.
Authors: Boddu P, Jain N Abstract The last decade has seen major progress in our understanding of the pathobiology of chronic lymphocytic leukemia (CLL) and the identification of potential new therapeutic targets. As a result, researchers have developed novel targeted therapies, several of which are already approved and many of which are in advanced stages of clinical development. These new agents are much less toxic than chemoimmunotherapy and may be preferred for their superior efficacy in patients with certain high-risk features, such as del(17p). The place of these therapies in CLL management is becoming better...
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

First-line use of novel hormonal agents in prostate cancer: a critical appraisal.
Authors: Raghavan D Abstract Castration has been the hallmark of the treatment of advanced prostate cancer for nearly a century. Conventional surgical or medical castration for the management of metastatic prostate cancer has been associated with an initial response rate greater than 60% to 70%, depending on the criteria employed. The median duration of the initial response is usually less than 3 to 5 years, however, depending on the extent of disease. The failure of disease to respond to castration has been associated with an increase in the production of adrenal androgens and/or the evolution of upregulated or mu...
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in pancreatic cancer from the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
Authors: PMID: 29742085 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in pancreatic cancer from the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium: commentary.
Authors: Bekaii-Saab T PMID: 29742086 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in metastatic colorectal cancer from the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
Authors: PMID: 29742087 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in metastatic colorectal cancer from the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium: commentary.
Authors: Grothey A PMID: 29742088 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in myeloproliferative neoplasms from the 2017 American Society of Hematology Annual Meeting and Exposition.
Authors: PMID: 29742089 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in myeloproliferative neoplasms from the 2017 American Society of Hematology Annual Meeting: commentary.
Authors: Verstovsek S PMID: 29742090 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in chronic lymphocytic leukemia from the 2017 American Society of Hematology Annual Meeting and Exposition.
Authors: PMID: 29742091 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in chronic lymphocytic leukemia from the 2017 American Society of Hematology Annual Meeting: commentary.
Authors: O'Brien SM PMID: 29742092 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium.
Authors: PMID: 29742093 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium: commentary.
Authors: Figlin RA PMID: 29742094 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in lymphoma from the 2017 American Society of Hematology Annual Meeting and Exposition.
Authors: PMID: 29742095 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in lymphoma from the 2017 American Society of Hematology Meeting: commentary.
Authors: Moskowitz CH PMID: 29742096 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in aggressive lymphoma from the 2017 American Society of Hematology Annual Meeting and Exposition.
Authors: PMID: 29742097 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in aggressive lymphoma from the 2017 American Society of Hematology Annual Meeting and Exposition: commentary.
Authors: Locke FL, Haroun F PMID: 29742098 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: Protests.
Authors: Kahl BS PMID: 29315281 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - January 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Chemotherapy-induced nausea and vomiting: strategies for prevention and treatment.
Authors: Schwartzberg LS PMID: 29315282 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - January 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Incorporating monoclonal antibodies into the management of multiple myeloma.
Authors: Mark TM PMID: 29315283 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - January 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Should autologous platelet-rich plasma be used in patients with hematologic disease?
Authors: Martí-Carvajal AJ PMID: 29315284 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - January 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Strategies to manage chemotherapy-induced peripheral neuropathy.
Authors: Sharma MR PMID: 29315285 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - January 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

ALK inhibitors in non-small cell lung cancer: how many are needed and how should they be sequenced?
Authors: Shaw AT PMID: 29315286 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - January 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Monitoring multiple myeloma.
Authors: Udd KA, Spektor TM, Berenson JR Abstract Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation in bone marrow of terminally differentiated plasma cells. MM is a slowly growing, heterogeneous disease with no known cure. Patients with MM have a median survival of approximately 5 years, during which they may experience significant morbidity. More reliable and rapid determination of changes in the clinical status of patients with MM is becoming increasingly important because of the increasing number of available treatments for these patients. Currently available tests for monitoring pa...
Source: Clinical Advances in Hematology and Oncology - January 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease.
Authors: Johnson B, Eng C Abstract An estimated 8200 men and women in the United States will receive a diagnosis of squamous cell carcinoma of the anal canal (SCCA) in 2017. Although SCCA is rare, accounting for 2.6% of gastrointestinal cancers, its incidence rate has been steadily increasing over the last few decades in the United States and around the world. More than 90% of cases of SCCA occur in the context of prior human papillomavirus (HPV) infection. To date, preventive vaccinations against HPV remain markedly underutilized. Most patients who have SCCA present with locoregional disease that is cured with che...
Source: Clinical Advances in Hematology and Oncology - January 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter from the Editor: In memory of Oliver Press, MD, PhD.
Authors: Kahl BS PMID: 29200412 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 5, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Real-world use of scalp cooling to reduce chemotherapy-related hair loss.
Authors: Rugo HS PMID: 29200414 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 5, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in the management of fungal infections.
Authors: McCarthy MW PMID: 29200415 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 5, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Patient-derived tumor xenograft models in drug development.
Authors: Hidalgo M PMID: 29200416 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 5, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research